Subscribe To
Glucose health presents a unique investment opportunity in the growing global diabetes epidemic
Glucose Health, Inc. is a micro-cap company that is on the leading edge of a long-term global macro trend that likely has a decades-long runway in fro...
July 19, 2022, 4:58 pm
Apollo endosurgery's new obesity endoscopic systems receive fda nod
Apollo Endosurgery Inc (NASDAQ: APEN) announced the marketing authorization of the Apollo ESG, Apollo ESG Sx, Apollo REVISE, and Apollo REVISE Sx S...
July 13, 2022, 10:31 am
Novo nordisk's (nvo) q1 earnings and sales beat estimates
Novo Nordisk (NVO) reports better-than-expected results for Q1. Sales are aided by growth in Diabetes and obes...
May 2, 2022, 12:47 pm
Novo nordisk lifts 2022 outlook after strong quarter, shares jump
Shares in Novo Nordisk jumped on Friday after the firm lifted its sales and operating profit guidance for the year on the back of forecast-beating fir...
April 29, 2022, 3:27 am
Novo nordisk: inflation hedge with upside potential
Novo Nordisk continues to hold its leading position in insulin and the anti-obesity drugs market space ...
April 27, 2022, 6:26 pm
Rhythm pharmaceuticals (rytm) down due to study design changes
Rhythm Pharmaceuticals (RYTM) modifies the design of its two genetic obesity disorder studies to focus ...
April 7, 2022, 3:48 pm
Rhythm pharma shares fall after modifications to setmelanotide trials in rare diseases of obesity
Rhythm Pharmaceuticals Inc (NASDAQ: RYTM) will modify its Phase 3 EMANATE and ongoing Phase 2 DAYBREAK trials of setmelanotide in rare genetic dise...
April 6, 2022, 12:03 pm
High drug prices due to ‘complex health care system' in the u.s., novo nordisk ceo says
Novo Nordisk CEO Lars Fruergaard Jørgensen joins Yahoo Finance Live to discuss the future of obesity a...
February 8, 2022, 11:09 am
High drug prices due to ‘complex health care system' in the u.s., novo nordisk ceo says
Novo Nordisk CEO Lars Fruergaard Jørgensen joins Yahoo Finance Live to discuss the future of obesity a...
February 8, 2022, 11:09 am
High drug prices due to ‘complex health care system' in the u.s., novo nordisk ceo says
Novo Nordisk CEO Lars Fruergaard Jørgensen joins Yahoo Finance Live to discuss the future of obesity a...
February 8, 2022, 11:09 am
Novo nordisk's (nvo) q4 earnings and sales beat estimates
Novo Nordisk's (NVO) earnings and revenues beat estimates in Q4. Sales are driven by growth in Diabetes and ob...
February 2, 2022, 1:50 pm
Novo nordisk's (nvo) q4 earnings and sales beat estimates
Novo Nordisk's (NVO) earnings and revenues beat estimates in Q4. Sales are driven by growth in Diabetes and ob...
February 2, 2022, 1:50 pm
Novo nordisk's (nvo) q4 earnings and sales beat estimates
Novo Nordisk's (NVO) earnings and revenues beat estimates in Q4. Sales are driven by growth in Diabetes and ob...
February 2, 2022, 1:50 pm
Novo nordisk posts upbeat q4 earnings, expects obesity drug shortages may soon be resolved
Novo Nordisk A/S NVO reported Q4 sales of DKK 38.3 billion, up 19% Y/Y on a reported basis and 16% on constant exchange rates (CER). Thousands of n...
February 2, 2022, 11:05 am
Novo nordisk posts upbeat q4 earnings, expects obesity drug shortages may soon be resolved
Novo Nordisk A/S NVO reported Q4 sales of DKK 38.3 billion, up 19% Y/Y on a reported basis and 16% on constant exchange rates (CER). Thousands of n...
February 2, 2022, 11:05 am
Novo nordisk posts upbeat q4 earnings, expects obesity drug shortages may soon be resolved
Novo Nordisk A/S NVO reported Q4 sales of DKK 38.3 billion, up 19% Y/Y on a reported basis and 16% on constant exchange rates (CER). Thousands of n...
February 2, 2022, 11:05 am
Altimmune's mid-stage pemvidutide study cleared by fda for obesity
The FDA has cleared Altimmune Inc's ALT Investigational New Drug (IND) application for its Phase 2 trial of pemvidutide for ...
January 31, 2022, 9:56 am
Altimmune's mid-stage pemvidutide study cleared by fda for obesity
The FDA has cleared Altimmune Inc's ALT Investigational New Drug (IND) application for its Phase 2 trial of pemvidutide for ...
January 31, 2022, 9:56 am
Altimmune's mid-stage pemvidutide study cleared by fda for obesity
The FDA has cleared Altimmune Inc's ALT Investigational New Drug (IND) application for its Phase 2 trial of pemvidutide for ...
January 31, 2022, 9:56 am